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Abstract
lnterpatient variabiff1y among medication doses has been a longstanding obstacle tor many prescribers. Some medications result in
increased morbidity and mortalffy in a small percentage of the population. For many years, the cause of such toxicities was unknown.
This myslery has been resolved by the discovery that the absence or
abnormaflty of specific genes that code for receptors, drug-targeted
proteins, drug transport mechanisms and drug metabolizing enzymes could alter how an affected individual will respond to a given
drug. One such incidence is the genetic polymorphism in thiopurine
s-methyftranferase (TPMT). In comprehending the mechanism of
this polymorphism, it is important to understand the metabolic pathway of thiopurine drugs. Through study of this pathway, researchers
began to look into whether other polymorphisms aside from TPMT
could be a source of the dose-rsiated toxicity with the thiopurlnes.
The prospect that this polymorphism may contribu1e to an increase
in number or exacerbation of side effects beyond the commonly presented bone marrow toxicitv also has been visited. Becoming more
aware of this genetic issue has presented the need to evaluate the
cost eifecttveness of genetic testing to counteract the expectOO cost
of treating extreme myelosuppression. Havtng knowledge of new
ptlamlacogenomic technology and the tests avattable can benefH
pharmacists in any setting. Pharmacists will be more prepared to
address patient concerns such as necessity and cost effectiveness.

Introduction
Recently, opinion articles were published in the New England Journal of
Medicine that discussed the controversies surrounding genetic testing
and, in particular, the marketing of this testing directly to consumers. 1•2
As pharmacists, we must be aware of these advances as we enter into
the "genomic" age and how they may impact our patients. In this article,
we present a case study of thiopurine s-methytransferase polymorphism.

genome project described over 1.4 million SNPs in the genome, but this
number continues to grow with extended research. 4 There are more than
30 families of drug-metabolizing enzymes in humans, all with genetic
variants causing the translation of such proteins to result in functional
differences. Patients who inherit a drug-metabolizing enzyme deficiency
must be treated with markedly different doses of the affected medications. Therefore, identifying genetic determinants of drug response can
help optimize the selection of drug therapy.

TPMT polymorphism
One of the most understood examples of a genetic polymorphism
is that of TPMT, which catalyzes the s-methylation of azathioprine,
mercaptopurine and thioguanine. 4 These medications, together called
the thiopurine drugs, are widely used in the treatment of leukemia,
inflammatory bowel diseases and severe rhematic diseases and for
immunosuppression following solid organ transplantation. 3 Azathioprine,
mercaptopurine and thiogunanine are all inactive prodrugs requiring
activation to thiopurine nucleotides. The active nucleotides compete with
endogenous nucleotides in many biochemical pathways, such as the
synthesis of DNA accounting for the immunosuppressive effects of these
drugs.5 These thiopurine drugs can undergo s-methylation by TPMT or
oxidation to thiouric acid by xanthine oxidase to be inactivated (figure 1).
Due to this alternative degradation pathway, the importance of the TPMT
polymorphism is diminished in most tissues. 6 However, hematopoietic
tissues do not have measurable xanthine oxidase activity, leaving
s-methylation as the major competing metabolic pathway. 3 Patients who
inherit TPMT deficiency accumulate excessive concentrations of the active thioguanine nucleotides in blood cells. This causes a heightened lmmunosuppressive reaction, leaving the patient at high risk for developing
bone marrow toxicity, resulting in pancytopenia, a reduction in red blood
cells, white blood cells and platelets. TPMT is not known to be involved
in any pathway for endogenous substrates. 4

Azathioprine

Ten to 28 percent of patients receiving azothioprine or mercaptopurine
therapy experience toxicity that requires stopping treatment or, in severe
cases, results in death. 3 Recognizing that this well-known occurrence
is related to a genetic polymorphism in thiopurine s-methyltranferase
(TPMT) has provided insights into the mechanism of intolerance and
offered strategies to avoid these toxicities.
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TMPT

Numerous medications exhibit wide interpatient variability in efficacy and
toxicity. Although nongenetic factors influence the effects of medications, the variability in response is many times due to single nucleotide
polymorphisms (SNPs) in genes encoding drug-metabolizing enzymes,
drug transporters and/or drug targets. Initial reports from the human
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Figure 1: Azathioprine Metabolism5
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Studies have been conducted to assess whether other genetic variations, aside from a TPMT polymorphism, affect azathioprine toxicity. 7
A study from the Department of Pharmacology at Pomeranian Medical
University in Poland investigated the role of another enzyme, inosine
triphosphate pyrophosphohydrolase (ITPA), which takes part further
down the metabolic pathway of thiopurines. The goal of the study was
to determine if azathioprine drug intolerance was related to ITPA allele
variants. ITPA catalyzes the dephosphorylation of inosine triphosphate
(ITP) to inosine monophosphate (IMP). A lack of ITPA leads to an
excess of ITP, which has not been proven to be pathogenic. However,
some researchers have noted that an accumulation of ITP during azathioprine therapy can produce metabolites (such as thio-ITP), which may
interfere with normal metabolic activity. The cohort study was conducted
with a large group of renal transplant patients. Patients were evaluated
for TPMT genetic polymorphisms and monitored for adverse effects of
low white blood cell (WBC) count and hepatotoxicity. It was observed
that ITPA had no effect on liver toxicity, and there was no statistical
evidence that ITPA altered WBC count. Though previously determined
in numerous other trials, the genetic effect of TPMT variations was
confirmed yet again. Authors of the study concluded that genetic testing
for ITPA during thioprine immunosuppressive therapy is not beneficial at
this time because there is no statistical significance that it plays a role in
adverse effects.
ft also has been determined that 10-30 percent of patients cannot
tolerate thiopurine therapy because of additional adverse events such
as hepatotoxicity, pancreatitis, influenza-like symptoms and nausea.8
A cohort study conducted in a small group of Greek pediatric patients
diagnosed with inflammatory bowel disease (IBD) observed the relationship between these adverse events and TPMT deficiency. A group of
just under 100 children (mean age 11.5 years) undergoing treatment of
IBD with thiopurine drugs was monitored for adverse events based on
their genetic makeup in regards to their ability to metabolize TPMT. This
study was conducted with the assumption that patients with a genetic
variant that translates to poor TPMT activity experienced higher rates of
the previously mentioned adverse events. Authors of the study concluded that, while dosages needed altering based on phenotype, the noted
adverse events did not correlate with genetic variation.
The TPMT genetic polymorphism serves as a good example of the
importance of pharmacogenetics because it has been well characterized
at the molecular, biochemical and clinical levels. 4 The importance of this
polymorphism is appreciated because its effect is highly penetrant when
TMPT-deficient patients are treated with standard doses. This means
that essentially 100 percent of TMPT-deficient patients will develop hematopoietic toxicity. Approximately 11 variant alleles have been associated with low TPMT enzymatic activity in humans. These alleles contain
SNPs leading to amino acid substitutions, formation of a premature stop
codon or destruction of a splice site. TPMT*3A is the most prevalent mutant in whites while TPMT*C is the predominant mutant allele in Asian,
African and African-American populations.

Conclusion
Polymerase chain reaction tests provide a means of prospectively
identifying these patients prior to drug therapy, thereby minimizing toxicities.9 Although all studies have been done based on rough estimates,
research points to the cost effectiveness of such testing by comparing
it to the expected cost of treating extreme myelosuppression. 10 It is
estimated that, by predetermining a case of TPMT deficiency, nearly
$3,000 could be saved in health care costs per patient. This data clearly
shows that, aside from the lives that can be saved, genetic testing has
an extremely positive impact from an economic standpoint. Even so,
health care providers must remember that cautious monitoring of blood
counts is required in all patients, since myelosuppression with thiopurine
drugs can still occur in patients with normal TPMT activity. 11
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